Modality
Peptide
MOA
TNFi
Target
GLP-1R
Pathway
Hedgehog
CRCGastric Ca
Development Pipeline
Preclinical
Aug 2023
→ May 2025
PreclinicalCurrent
NCT04714580
1,572 pts·Gastric Ca
2023-08→2025-05·Active
1,572 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-2110mo agoInterim· Gastric Ca
Trial Timeline
Q42024Q2Q3Q42025Q2
Preclinical
Active
Catalysts
Interim
2025-05-21 · 10mo ago
Gastric Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04714580 | Preclinical | Gastric Ca | Active | 1572 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R |